Asset Details
Do you wish to reserve the book?
Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials
Do you wish to request the book?
Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials
2007
Overview
Our objective was to review all published trials of coenzyme Q
10
for hypertension, assess overall efficacy and consistency of therapeutic action and side effect incidence. Meta-analysis was performed in 12 clinical trials (362 patients) comprising three randomized controlled trials, one crossover study and eight open label studies. In the randomized controlled trials (
n
=120), systolic blood pressure in the treatment group was 167.7 (95% confidence interval, CI: 163.7–171.1) mm Hg before, and 151.1 (147.1–155.1) mm Hg after treatment, a decrease of 16.6 (12.6–20.6,
P
<0.001) mm Hg, with no significant change in the placebo group. Diastolic blood pressure in the treatment group was 103 (101–105) mm Hg before, and 94.8 (92.8–96.8) mm Hg after treatment, a decrease of 8.2 (6.2–10.2,
P
<0.001) mm Hg, with no significant change in the placebo group. In the crossover study (
n
=18), systolic blood pressure decreased by 11 mm Hg and diastolic blood pressure by 8 mm Hg (
P
<0.001) with no significant change with placebo. In the open label studies (
n
=214), mean systolic blood pressure was 162 (158.4–165.7) mm Hg before, and 148.6 (145–152.2) mm Hg after treatment, a decrease of 13.5 (9.8–17.1,
P
<0.001) mm Hg. Mean diastolic blood pressure was 97.1 (95.2–99.1) mm Hg before, and 86.8 (84.9–88.8) mm Hg after treatment, a decrease of 10.3 (8.4–12.3,
P
<0.001) mm Hg. We conclude that coenzyme Q
10
has the potential in hypertensive patients to lower systolic blood pressure by up to 17 mm Hg and diastolic blood pressure by up to 10 mm Hg without significant side effects.
Publisher
Nature Publishing Group UK,Nature Publishing,Nature Publishing Group
Subject
/ Arterial hypertension. Arterial hypotension
/ Biological and medical sciences
/ Blood Pressure - drug effects
/ Clinical manifestations. Epidemiology. Investigative techniques. Etiology
/ Humans
/ Hypertension - physiopathology
/ Medicine
/ Patients
/ Pharmacology. Drug treatments
/ Placebos
/ Randomized Controlled Trials as Topic
/ Ubiquinone - adverse effects
/ Ubiquinone - analogs & derivatives
